article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

Expert Review of Clinical Pharmacology. Plant cannabinoids: a neglected pharmacological treasure trove. British journal of pharmacology. 2014 Jan;32(1):40-51. 2023 Mar 4;16(3):257-66. Mechoulam R. 2005 Dec;146(7):913-5. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs.

Medical 98
article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

Approximately 43% of people with MCI develop dementia due to Alzheimer’s disease within 5 years (Roberts, 2014) (Figure 1). Personalized care relies on pharmacological and non-pharmacological interventions aimed at (temporarily) relieving cognitive and non-cognitive symptoms (Alzheimer’s Association, n.d.; Emblad, S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. New therapies are under development in neurology, cardiology, and psychiatry.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

Regulatory pathways in the EU The EU regulatory framework is, unsurprisingly, similar to that in the UK (as the UK framework derives from the EU Directives) and consists of the Traditional Use Scheme and full MA. Available from: [link] Apply for a traditional herbal registration (THR) [Internet]. 2024 [cited 2024May]. Regulation of herbal medicines.

Marketing 103